ABSTRACT
From experimental and clinical studies it became clear that combined chemotherapy prolonged the disease-free intervals and the survival time in tumor patients. In children suffering from osteogen sarcoma diffuse intravascular coagulation (DIC) may develop after a high dose of methotrexate treatment; microhemolytic anemia and DIC were observed in connection with chemotherapy of advanced adenocarcinoma of the stomach. In hemotological malignomas one of the well-known hemostasis alterations caused by cytostatic treatment is DIC in promyelocytic leukemia. The hemostasis of the two patient groups investigated was different before therapy. In childhood acute lymphoid leukemia, an increasing fibrinogen metabolism and DIC were observed during the induction of chemotherapy. Tumor patients had been operated before the adjuvant chemotherapy; the complete eradication of the primary tumor was unsuccessful in either group of the patients. Hypercoagulability was characteristic of tumor patients and hypocoagulability for non-Hodgkin’s lymphoma patients.
